Adventrx Pharmaceuticals is focused on developing proprietary product candidates. Adventrx’s lead product candidate ANX-188 is an agent that improves microvascular blood flow, developed as a potential therapeutic for a wide range of diseases and conditions, such as complications arising from sickle cell disease. The company is also developing ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. For more information visit the company’s Web site at www.adventrx.com
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
Let us hear your thoughts below: